1-(1-acetylpiperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one | 23305-43-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 1-(1-acetylpiperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one
• 英文别名: 1-(1-Acetyl-piperidin-4-yl)-1,3-dihydro-benzimidazol-2-one；3-(1-acetylpiperidin-4-yl)-1H-benzimidazol-2-one
• CAS: 23305-43-3
• 化学式: C₁₄H₁₇N₃O₂
• 分子量: 259.308
• InChiKey: FJWQUDJXXMCZGT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  19
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  52.6
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  4-（2-酮酸-1-苯并咪唑）哌啶 在 乙酸酐 作用下， 以 水 、 溶剂黄146 为溶剂， 以77%的产率得到1-(1-acetylpiperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one
  参考文献：
  名称：

  US6180649

  摘要：

  公开号：

文献信息

• Inhibition of activated STAT5 in Bcr/Abl expressing leukemia cells with new pimozide derivatives
  作者：Riccardo Rondanin、Daniele Simoni、Romeo Romagnoli、Riccardo Baruchello、Paolo Marchetti、Cristiana Costantini、Sara Fochi、Giacomo Padroni、Stefania Grimaudo、Rosaria Maria Pipitone、Maria Meli、Manlio Tolomeo

  DOI：10.1016/j.bmcl.2014.07.069

  日期：2014.9

  STATs are transcription factors acting as intracellular signaling after stimulation with cytokines, growth factors and hormones. STAT5 is also constitutively active in many forms of cancers, including chronic myelogenous leukemia, acute lymphoblastic leukemia and Hodgkin's lymphoma. Recently, literature reported that the neuroleptic drug pimozide inhibits STAT5 phosphorylation inducing apoptosis in CML cells. We undertook an investigation from pimozide structure, obtaining simple derivatives with cytotoxic and STAT5-inhibitory activity, two of them markedly more potent than pimozide. (C) 2014 Elsevier Ltd. All rights reserved.
• US06180649B2
  申请人：——

  公开号：——

  公开（公告）日：——
• 1-(4-PIPERIDYL)-BENZIMIDAZOLES HAVING NEUROTROPHIC ACTIVITY
  申请人：NEUROSEARCH A/S

  公开号：EP0898568A1

  公开（公告）日：1999-03-03
• HAEMATOPOIETIC-PROSTAGLANDIN D2 SYNTHASE INHIBITORS
  申请人：Smythe Mark Leslie

  公开号：US20130137684A1

  公开（公告）日：2013-05-30

  The present invention generally relates to compounds that inhibit haematopoietic-prostaglandin D 2 synthase (H-PGDS), to compositions containing them and to their use in treating or preventing conditions and diseases associated with H-PGDS, such as allergies and inflammation.
• Pharmaceutical Compound
  申请人：IOMET PHARMA LTD

  公开号：US20160367564A1

  公开（公告）日：2016-12-22

  Provided is a tryptophan-2,3-dioxygenase (TDO) and/or indoleamine-2,3-dioxygenase (IDO) inhibitor compound for use in medicine, which compound comprises the following formula: wherein X 2 , X 4 , X 10 , and X 11 may be the same or different and each is independently selected from C and N; X 1 , X 3 , X 5 , X 6 , X 7 , X 8 , and X 9 may be the same or different and each is independently selected from C, N and O; each bond having a dotted line may independently be a double bond or a single bond, provided that valencies at each atom are maintained; the dotted lines joining X 4 with the carbon atoms either side of X 2 are single bonds, and are only present when X 2 is absent, X 3 is absent and X 4 is C, and when these bonds are present the ring carbons on each side of X 2 are not directly bonded to each other; each R 1 may be present or absent and may be the same or different and is selected from H and a substituted or unsubstituted organic group, provided that the number of R 1 groups present is such that the valency of X 1 is maintained; each R 12 , R 13 , R 13′ , R 14 , R 15 and R 15′ may be present or absent and may be the same or different and each is independently selected from H and a substituted or unsubstituted organic group, provided that the number of such R groups present is such that the valency of the ring carbon atoms is maintained; R 16 may be present or absent and is selected from H and a substituted or unsubstituted organic group, provided that the number of R 16 groups present is such that the valency of X 2 is maintained; each R 17 may be present or absent and may be the same or different and is independently selected from H and a substituted or unsubstituted organic group, provided that the number of R 17 groups present is such that the valency of X 3 is maintained; each R 2 , R 3 , R 4 , and R 5 may be present or absent and may be the same or different and is selected from H and a substituted or unsubstituted organic group, provided that the number of such R groups present is such that the valencies of X 6 , X 7 , X 8 , and X 9 are maintained; each R 7 , R 8 and R 9 may be present or absent and may be the same or different and is selected from H and a substituted or unsubstituted organic group, provided that the number of such R groups present is such that the valencies of X 10 , X 11 , and X 5 are maintained; and R 6 is selected from H and a substituted or unsubstituted organic group, preferably H and a substituted or unsubstituted C 1 -C 6 alkyl group; and wherein any R group may form a ring with any other R group on an adjacent and/or proximal atom.